Applied Finance IVS US SMID ETF (IVSS)

The Applied Finance IVS US SMID ETF (ticker IVSS) is a U.S.-focused fund that holds small and mid-size companies selected by systematic quantitative screening for value and financial strength. It targets investors who believe smaller, cheaper domestic firms offer long-term opportunity.

“Smaller doesn’t mean riskier if the fundamentals are sound.”

SMID value as a category

The fund occupies a middle ground between the broad U.S. market indices and micro-cap specialists. Small and mid-cap stocks — loosely, those with market capitalizations between a few hundred million and several billion dollars — have characteristics that set them apart. They are often younger, faster-growing, and less widely followed than mega-cap names, which creates two opportunities: pockets of mispricing when pessimism is unwarranted, and genuine growth potential that the market has not yet recognized or priced in.

IVSS applies a quantitative value filter to this universe. The model identifies companies trading at low multiples of earnings, book value, or cash flow, with solid balance sheets and consistent profitability. The aim is to capture smaller firms that are cheap for reasonable reasons — not permanently broken companies, but undiscovered or temporarily out of favour.

Why SMID can be appealing

A portfolio heavy in mega-cap indices (which many U.S. investors naturally accumulate) is missing the entire small and mid-cap opportunity set. IVSS offers a systematic way to tap that opportunity without relying on individual stock picking. The quantitative approach removes emotion and provides consistency: the same screening criteria apply to every candidate, making the process repeatable and transparent.

Small and mid-cap companies are also more likely than their mega-cap peers to be acquired or to experience significant operational change, which creates the possibility of sudden price appreciation. A value filter increases the odds that an investor is buying into those companies at a price that leaves room for upside.

The illiquidity tradeoff

The major constraint on IVSS is that individual SMID stocks trade less frequently than mega-cap names. If an investor needs to sell a large block of shares, moving the price is a real risk. For the fund itself, maintaining liquidity in holdings requires discipline — the fund cannot own stocks so small that trading becomes impossible. The Applied Finance approach keeps holdings within a range where liquidity, though tighter than a mega-cap index, is still workable for most transaction sizes.

Bid-ask spreads on individual SMID stocks are also wider than on blue chips, which raises the cost of trading. Over time, these friction costs matter. However, the value premium and growth potential available in this space can more than offset that drag if the selection is sound.

Concentration and volatility

Because the SMID universe is much smaller than the large-cap universe, IVSS must concentrate its holdings in a way that a mega-cap value fund does not. The fund holds roughly 100 to 150 stocks, but even then, the top 10 or 20 represent a larger percentage of assets than they would in a broader fund. This means that key stock-specific decisions have outsized impact. When a single holding stumbles, it affects the fund more noticeably.

SMID stocks are also more volatile day-to-day and suffer more severely in market downturns. In a recession or financial stress, small companies with limited cash and restricted access to capital suffer faster than their larger competitors. IVSS investors should expect larger swings in net asset value, especially during crisis periods.

Costs and tax efficiency

IVSS has a moderate expense ratio reflective of the ongoing screening and rebalancing required to maintain the quantitative model. The fund’s turnover is moderate — not as low as a buy-and-hold index fund, but not high enough to create significant tax drag for taxable account holders. The quarterly rebalancing schedule is predictable and rules-driven.

Being an ETF, IVSS trades on an exchange, so investors can buy or sell intraday at market prices rather than waiting for end-of-day net-asset-value pricing. For large orders, the exchange liquidity is usually better than would be the case with a mutual fund structure.

Who holds IVSS and why

IVSS suits investors who already have broad U.S. market exposure and want to tilt a portion of their portfolio toward small and mid-cap value. It is also appropriate for advisors constructing a diversified multi-asset allocation who view SMID value as a distinct return source.

The fund is not suitable for investors with low risk tolerance or short time horizons. The combination of small-cap volatility and value-factor cyclicality means IVSS can trail the broad market for years at a time. Anyone deploying capital here must be comfortable with that possibility.

Key risks

Value as a factor persistently underperforms during growth-dominated markets. IVSS will lag in those periods, and that lag can last multiple years. Small-cap leverage in a recession hits IVSS harder than the broader market — if the underlying companies struggle to generate cash, the value premium can reverse sharply downward.

The illiquidity and wide spreads in individual SMID stocks also mean that unexpected forced selling (a fund closure or redemption spike) can push prices down faster in this corner of the market than elsewhere. This is rare, but it is a tail risk inherent to SMID investing.

Researching IVSS

Start with the fund’s prospectus and fact sheet, which describe the quantitative criteria and show the historical performance relative to broad U.S. indices and a dedicated small-cap benchmark like the Russell 2000. Compare IVSS against both a broad small-cap value index and competing SMID-focused quantitative funds to assess whether the screening is delivering genuine edge or merely charging for a style bet.

Monitor the fund’s sector and size breakdown — during strong growth years, SMID valuations can become stretched, and exposure to high-risk sectors like small-cap technology or biotech can surge. Watch for when valuations reset, as that is often when the fund’s opportunity set refreshes.